Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

(GLOBE NEWSWIRE) — Genevant Sciences, a leading nucleic acid delivery company with world- class
platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has
entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine
Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an
in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds
upon a joint research and development collaboration in hemophilia A between Novo Nordisk and
2seventy bio previously announced by 2seventy bio.

“We are thrilled to work with Novo Nordisk in the development of a potentially transformative gene
editing treatment for a patient population in need of novel therapeutic approaches,” said Pete
Lutwyche, Ph.D., President and Chief Executive Officer of Genevant Sciences. “This important
collaboration highlights the role that state-of-the-art LNP delivery technology can play in
harnessing the massive potential of RNA-based medicines.”

“We recognize the importance of delivery to the success of RNA therapeutics and are excited to now
be working directly together with Genevant to bring a next-generation gene editing therapeutic to
individuals living with hemophilia A,” said Karina Thorn, corporate vice president of RNA and Gene
Therapies at Novo Nordisk.

The agreement announced today arises from the exercise of an option under a prior agreement between
Genevant and 2seventy bio and subsequently assigned by 2seventy bio to Novo Nordisk. The financial
terms of the agreement are in accordance with the option agreement negotiated between Genevant and
2seventy bio and as announced by 2seventy bio in January 2022.

About Genevant Sciences
Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, an
expansive lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in
nucleic acid drug delivery and development. The Company’s scientists have pioneered LNP delivery of
nucleic acids for over 20 years, and the Company’s LNP platform, which has been studied across more
than a dozen discrete product candidates and is the delivery technology behind the first and only
approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications,
including vaccines, therapeutic protein production, and gene editing. For more
information, please visit